A running-in model for the reciprocating sliding of Nylon 6.6 against stainless steel

Results are presented of investigations of the running-in period in reciprocating sliding of a semicrystalline polymer, Nylon 6.6, on metal. A correlation was established between the changes in transfer film geometry and both the friction coefficient and the wear rate variations during a single stroke, as well as with sliding time. The role of wear products in running-in was found to be the determining factor. In order to avoid any unspecified influence of frictional heat variation on the sliding process, the counter specimen temperature was kept constant. Significant correlations, between both local and mean coefficients of friction and local and total areas of transfer film respectively, were found. The latter relation shows the existence of two different types of running-in process which depend on whether, initially, adhesive or abrasive wear mechanisms prevail. In both cases, the building up of the transfer film together with roll-like wear particles create several types of interactions between the rubbing bodies. These interactions, subsequently called subprocesses, have their own different specific coefficients of friction and can exist on the sliding track solely or in combination. They also change their distribution over the track and finally create a variation in the mean friction coefficient with time. This variation is expressed as a function of the total area fraction of transfer film spreading with time. It is also shown that changes in wear rate coincide with variations in mean friction coefficient. The presented model can also be extended qualitatively to other semicrystalline polymers

Badanie mechanizmów tarcia i zużycia węglika spiekanego z powłoką TiAlN w parze ze stopem tytanu Ti6Al4V za pomocą tribometru pin-on-disc

The tribological behavior of the PVD-TiAlN coated carbide inserts in dry sliding against two-phase (α-β) titanium alloy,Ti6Al4V grade, was investigated. A modified pin-on-disc device was used to conduct experiments under variable normal load and sliding speed. Scanning electron microscopy (SEM) and X-ray micro-analyses by EDS were applied for observations of wear scars and wear products. It was revealed that the increase of sliding speed contributes to decreasing the friction coefficient under a low normal force, whereas the increase of the normal loading causes the friction coefficient is less sensitive to changes in the sliding speed and its values are equal to μ = 0.26-0.34. The adhesive nature of wear along with severe abrasive action of the Ti alloy were documented.W artykule przestawiono wyniki badań dotyczące tribologicznego zachowania się płytek skrawających z węglika spiekanego pokrytego powłoką TiAlN w skojarzeniu z dwufazowym (α-β) stopem tytanu Ti6Al4V w warunkach tarcia suchego. W badaniach użyto zmodyfikowane urządzenie typu pin-on-disc, które umożliwia przeprowadzenie badań eksperymentalnych ze zmiennym obciążeniem normalnym i zmienną prędkością poślizgu. Do obserwacji śladów i produktów zużycia zastosowano mikroskopię skaningową (SEM) i mikroanalizę rentgenowską (EDS). Wykazano, że wzrost prędkości poślizgu przyczynia się do zmniejszenia współczynnika tarcia, jeśli stosuje się małe siły normalne, natomiast wzrost obciążenia normalnego powoduje, że współczynnik tarcia jest mniej wrażliwy na zmiany prędkości poślizgu i jego wartości wynoszą μ = 0,26-0,34. Udokumentowano adhezyjny mechanizm zużycia łącznie z silnym oddziaływaniem ściernym stopu tytanu

Friction and wear of lubricated M3 class 2 sintered high speed steel with and without TiC and MnS additives.

NoM3/2 sintered high speed steel and composite materials processed by initial admixing of 5 wt.% TiC (to decrease wear) and 5 wt.% MnS (to minimise friction) powders, singly and in combination, were assessed in pin-on-disc tribometers specially constructed to simulate use in the automotive valve train. Pins were of the sintered materials and the mating tribological material discs of T1 high speed steel. For comparison with existing conventional materials, identical tests were performed with discs and pins of two types of spheroidal cast iron. Testing at 110 °C, employing a few drops of fresh Shell Helix Standard SAE: 15W-40, API: SJ/CF oil, in daily segments of 5000 m of sliding distance was carried out until the break of the boundary film and appearance of the early signs of seizure. Accordingly the conditions were initially elastohydrodynamic, then mixed lubrication, then boundary, and finally decaying boundary. In comparison with the baseline cast iron system, the friction, wear and lifetime performance of all the high speed steel systems was markedly superior. MnS further lowered the coefficient of friction and TiC increased the load carrying capacity of M3/2 steel. The lifetime, test distance until seizure, was the most discriminating parameter between the high speed steel systems, being 1.5¿3 times longer for the unmodified M3/2 than the composites and 10 times longer than that of the cast irons system

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

Abstract: Background: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)\u2013defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). Methods: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. Results: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52\u20131.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. Conclusions: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01994720.Abstract: BACKGROUND: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). METHODS: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. RESULTS: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52-1.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. CONCLUSIONS: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs